Skip to main content

ANALISIS ULTRA-SENSIBLE Y MINIMAMENTE INVASIVO DE LA ENFERMEDAD MINIMA RESIDUAL EN SANGRE PERIFERICA EN PACIENTES CON MIELOMA MULTIPLE

PI21/01917

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, A.
  • Vazquez, I.
  • Cuenca, I.
  • Rosa-Rosa, J.M.|||0000-0003-0806-6453
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Jimenez, C.
  • Fernandez-Mercado, M.
  • Larrayoz, M.J.
  • Gutierrez, N.C.
  • Fernandez-Guijarro, M.
  • Gonzalez-Calle, V.
  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Alegre, Adrian|||0000-0002-2423-822X
  • Escalante, F.
  • de la Rubia, Javier|||0000-0002-8354-768X
  • Teruel, A.I.
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Lopez-Jimenez, Javier|||0000-0002-2969-3002
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Puig, Noemí|||0000-0001-7535-3861
  • Paiva, Bruno|||0000-0003-1977-3815
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J.|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Rios, R.
  • Sureda, Anna|||0000-0002-1238-6970
  • Blanchard, María Jesús
  • Martinez-Martinez, R.
  • Moraleda, J. M.
  • Bargay, Joan|||0000-0002-6739-3916
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Palomera, L.
  • Gonzalez-Montes, Y.
  • Martí, J.M.
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Arguiñano, J.M.
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Gonzalez, A.P.
  • Casado Montero, Luis Felipe|||0000-0002-8171-0674
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, Alejandro
  • Vázquez Urio, Iria
  • Cuenca, Isabel
  • Rosa-Rosa, Juan Manuel
  • Ariceta, Beñat
  • Jiménez, Cristina
  • Fernández-Mercado, Marta
  • Larráyoz, María José
  • Gutiérrez, Norma C.
  • Fernández-Guijarro, M.
  • González-Calle, Verónica
  • Rodríguez-Otero, Paula
  • Oriol, Albert
  • Rosiñol, Laura
  • Alegre, Adrián
  • Escalante, Fernando
  • Rubia, Javier de la
  • Teruel, A. I.
  • Arriba, Felipe de
  • Hernández, Miguel-Teodoro
  • López-Jiménez, Javier
  • Ocio, Enrique María
  • Puig, Noemí
  • Paiva, Bruno David Lourenço
  • Lahuerta, Juan-José
  • Bladé, Joan
  • San-Miguel, Jesús F.
  • Mateos, María-Victoria
  • Martínez-López, Joaquín
  • Calasanz, María José
  • García-Sanz, Ramón
  • GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting., This work was partially supported by Amgen, the Asociación Española Contra el Cáncer (AECC, PROYE20047GUTI), the Instituto de Salud Carlos III (ISCIII, PI21/01917 and PMP21/00015), the Centro de Investigación Biomédica en Red (CIBERONC CB16/12/00233, CB16/12/00284, CB16/12/00369 and CB16/12/00489), the Cancer Research UK (C355/A26819) and FC AECC and AIRC under the Accelerator Award Program, and 'Una manera de hacer Europa' (Innocampus; CEI-2010-1-0010). CJ was supported by the ISCIII (CD19/00030), AM-H by the European Social Fund through the IBSAL, the ISCIII (FI19/00320), the International Myeloma Society and the Spanish Society of Hematology (co-funded by Janssen). All Spanish funding is co-sponsored by the European Union FEDER program. MVM is the president of the Spanish Society of Hematology. JJL is the president of the GEM-PETHEMA group.